Working to Eradicate Gynecologic Cancers

Poster Session A

Saturday, March 28, 2015: 9:55 AM-6:30 PM
Salon C-D (Hilton Chicago)
Description:
9:55 AM
160
Breast cancer is common in women with ovarian malignant mixed Müllerian tumors
R. M. Whynott
University of South Florida, Tampa, FL
 
9:55 AM
161
Who's On First Or Who Knows How: Surgical Management of Mammary Carcinoma On A Gynecolgic Oncology Service
S. J. Kapnick
I. Kapnick Memorial Cancer Consortium, Jupiter, FL
 
9:55 AM
162
Treatment outcomes for patients with locally advanced cervical cancer in a low resource setting: experience at a single institution in Tegucigalpa, Honduras
H. H. Cooper1, E. B. Pereira2, P. G. Zelayas1, W. T. Creasman3, F. V. Price4 and L. T. Chuang2
1The National Autonomous University of Honduras, Tegucigalpa, Honduras, 2Icahn School of Medicine at Mount Sinai, New York, NY, 3Medical University of South Carolina, Charleston, SC, 4West Penn Allegheny Health System, Pittsburgh, PA
 
9:55 AM
163
Factors associated with post-cryotherapy wound healing among HIV-infected women in a Sub-Saharan African setting
K. S. Pfaendler1, V. V. Sahasrabuddhe2, K. Katundu3, M. H. Mwanahamuntu3,4, S. Kapambwe3, S. H. Vermund2 and G. P. Parham3,5
1UC Irvine Medical Center, Orange, CA, 2Vanderbilt University School of Medicine, Nashville, TN, 3Centre for Infectious Disease Research in Zambia, Lusaka, Zambia, 4University of Zambia School of Medicine, Lusaka, Zambia, 5University of North Carolina at Chapel Hill, Chapel Hill, NC
 
9:55 AM
164
Outcomes for partial metabolic response on post therapy positron emission tomography for cervical cancer: role of surgical intervention
S. L. Williams1, I. Wilkinson-Ryan2, S. Lederhandler1, N. Al-Hammadi1, A. R. Hagemann2, P. H. Thaker2, M. A. Powell2, D. G. Mutch2, P. W. Grigsby1 and J. K. Schwarz1
1Washington University School of Medicine, St Louis, MO, 2Washington University School of Medicine, St. Louis, MO
 
9:55 AM
165
Incidence of human papillomavirus, cervical dysplasia and cervical cancer among women in Liberia: assessing the burden of disease
A. M. Beddoe1, E. B. Pereira1, W. Jallah2, E. Solomon1, A. Dottino3 and P. Dottino1
1Icahn School of Medicine at Mount Sinai, New York, NY, 2Hope for Women International, Monrovia, Liberia, 3Georgetown University Health Center, Washington, DC
 
9:55 AM
166
Factors influencing acceptability of the HPV vaccine among urban women
L. Cory1, A. F. Haggerty1, W. T. Hwang1 and C. Chu2
1University of Pennsylvania, Philadelphia, PA, 2Fox Chase Cancer Center, Philadelphia, PA
 
9:55 AM
167
Cervical cancer screening in rural Guatemala
M. K. Frey1, E. Gertz2 and T. Shirazian2
1New York University School of Medicine, New York, NY, 2Mount Sinai Hospital, New York, NY
 
9:55 AM
168
Catastrophic intraperitoneal recurrence in patients with early cervical cancer treated with laparoscopic/robotic radical hysterectomy
T. W. Kong1, S. J. Chang1, J. H. Son1, S. W. Kang2, J. Paek1, Y. L. Lee3, E. J. Lee2 and H. S. Ryu2
1Ajou University Hospital, Suwon, South Korea, 2Ajou University School of Medicine, Suwon, South Korea, 3Ajou University School of Medicine, Suwon, Gyunggi-do, South Korea
 
9:55 AM
169
Quality improvement audit of cervical cancer screening in Mbeya, Tanzania
E. R. Hope and S. M. Petersen
Walter Reed National Military Medical Center, Bethesda, MD
 
9:55 AM
170
Laparoscopic surgical management in early-stage cervical cancer: analysis of surgical and oncological outcome
C. Garabedian, B. Merlot, L. Bresson, E. Tresch, F. Narducci and E. Leblanc
Centre Oscar Lambret, Lille, France
 
9:55 AM
171
ASC-US and LSIL triage in Korean women: revisiting the 2012 ASCCP screening guidelines
K. J. Min, S. Y. Yang, Y. J. Koo, J. H. Hong and J. K. Lee
Guro Hospital, Korea University College of Medicine, Seoul, South Korea
 
9:55 AM
172
Prognostic value of preoperative intratumoural FDG uptake heterogeneity in uterine cervical cancer
H. H. Chung
Seoul National University College of Medicine, Seoul, South Korea; Seoul National University, Seoul, South Korea
 
9:55 AM
173
Chemosensitizing effect of aqueous extract of sweet fennel in cisplatin treated HeLa cells
K. H. Sait
King Abdulaziz University, Calgary, AB, Canada
 
9:55 AM
174
Treatment compliance among medically underserved women receiving chemoradiation for locoregionally advanced cervical cancer
G. L. Hsieh, S. Linesch, A. Sajjad, M. L. Anderson and M. Ludwig
Baylor College of Medicine, Houston, TX
 
9:55 AM
175
Upfront laparoscopic surgery in Ib2 cervical cancer: surgical and survival outcomes
F. Ferrari1, G. Fachechi1, K. Gubbala1, H. Soleymani majd2, R. Garruto Campanile2 and R. Tozzi1,2
1Oxford University Hospital, Oxford, United Kingdom, 2Oxford University Hospitals NHS Trust, Oxford, United Kingdom
 
9:55 AM
176
The impact of lymph node density (LND) on outcome in pelvic lymph node-positive cervical cancer patients
A. Yoon1, Y. Y. Lee1, C. H. Choi1, W. Y. Kim2, T. J. Kim3, J. W. Lee3, B. G. Kim3 and D. S. Bae3
1Samsung Medical Center, Seoul, South Korea, 2Kangbuk Samsung Hospital, Seoul, South Korea, 3Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
 
9:55 AM
177
Neoadjuvant brachytherapy and chemotherapy followed by radical surgery in Stage IB2 and IIA cervical cancer: a retrospective comparison with chemoirradiation
Y. Ma
Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin, China
 
9:55 AM
178
Cervical cancer recurrence risk evaluation based on SUV(max) during initial 18F-FDG PET/CT
A. Gubbi1, J. E. Kendrick IV1, S. Ahmad1 and S. Kacheria2
1Florida Hospital Cancer Institute, Orlando, FL, 2Florida Hospital Cancer Institute and UCF College of Medicine, Orlando, FL
 
9:55 AM
179
Salvage laparoscopic lymphadenectomy combined to chemotherapy and/or radiation therapy for isolated para-aortic nodal recurrence of cervical cancer: morbidity and outcomes of a case series
G. F. Cintra, M. A. Vieira, C. E. M. D. C. Andrade, E. B. Simioni, R. Dos Reis, J. S. Nunes, R. J. Affonso Jr. and A. T. Tsunoda
Barretos Cancer Hospital, Barretos, Brazil
 
9:55 AM
180
The increase in early detection and associated improved survival of cervical cancer in the US: a ten-year study of 6,414 patients
J. S. Chapman1, K. Blansit2, A. B. Gardner2, L. M. Chen1, R. A. Brooks1, S. M. Ueda1, D. S. Kapp3 and J. K. Chan4
1UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, 2Palo Alto Medical Foundation Research Institute, Palo Alto, CA, 3Stanford University, Stanford, CA, 4California Pacific & Palo Alto Medical Foundation / Sutter Research Institute, San Francisco, CA
 
9:55 AM
181
Molecular signaling pathways associated with squamous-cell carcinoma of the cervix cisplatin-resistance
B. R. Khulpateea1, D. Marchion2, Y. Xiong2, B. Boac3, F. Abbasi2, C. McClung3, P. Judson3, S. M. Apte2, R. M. Wenham2 and J. M. Lancaster2
1The Women's Institute for Gynecologic Cancer and Special Pelvic Surgery, Tampa, FL, 2H. Lee Moffitt Cancer Center, Tampa, FL, 3H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
 
9:55 AM
182
Cervical adenocarcinoma in situ: an institutional retrospective review of surgical management and outcome
M. Pasternak, E. Jorgensen, M. Azodi, E. S. Ratner, T. J. Rutherford, A. Santin, P. E. Schwartz and D. A. Silasi
Yale University School of Medicine, New Haven, CT
 
9:55 AM
183
Radical hysterectomy: programmatic change to reduce laparotomy rate while maintaining oncologic outcome for early stage cervical cancer
G. J. Gardner, V. Sioulas, R. Keller, G. Degerli, I. D. Benrubi, E. Jewell, Y. Sonoda, N. R. Abu-Rustum, R. R. Barakat and M. M. Leitao
Memorial Sloan Kettering Cancer Center, New York, NY
 
9:55 AM
184
QRF1 expression results in oncogenic potential and poor prognosis in cervical cancer
D. B. Chay1, H. Cho1, S. Kim2, Y. T. Kim1 and J. H. Kim3
1Yonsei University College of Medicine, Seoul, South Korea, 2Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, 3Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
 
9:55 AM
185
Postoperative intensive-modulated radiation therapy (IMRT) with or without concurrent chemotherapy for intermediate- and high-risk cervical cancer patients
Y. J. A. Chen
Taichung Veterans General Hospital, Taichung, Taiwan
 
9:55 AM
186
Role of neoadjuvant chemotherapy in the management of advanced ovarian yolk sac tumor
Y. Jiaxin, K. Shen and D. Cao
Peking Union Medical College Hospital, Beijing, China
 
9:55 AM
187
Deep tissue hyperthermia for recurrent/progressive malignancies
G. Del Priore
Cancer Treatment Centers of America, Newnan, GA; Morehouse School of Medicine, Atlanta, GA
 
9:55 AM
188
Adding a molecular profile test to make use of bevacizumab more affordable in ovarian cancer
J. P. Geisler1, A. Walter2 and K. J. Manahan1
1Georgia Regents University/University of Georgia Medical Partnership, Athens, GA, 2The University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK
 
9:55 AM
189
The impact of body mass index on intraperitoneal chemotherapy outcomes
M. R. Davis1, E. M. Aviki2, J. A. Rauh-Hain2, M. J. Worley Jr.1, R. S. Berkowitz1, J. O. Schorge2, M. G. Muto1, W. B. Growdon2, N. S. Horowitz3 and M. del Carmen4
1Brigham and Women's Hospital/Harvard University, Boston, MA, 2Massachusetts General Hospital/Harvard University, Boston, MA, 3Harvard University, Boston, MA, 4Massachusetts General Hospital, Boston, MA
 
9:55 AM
190
Trends in FDA approval of oncology drugs: have we made progress?
N. Young-Lin1, K. Blansit2, A. B. Gardner2, J. S. Chapman1, D. S. Kapp3 and J. K. Chan4
1UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, 2Palo Alto Medical Foundation Research Institute, Palo Alto, CA, 3Stanford University, Stanford, CA, 4California Pacific & Palo Alto Medical Foundation / Sutter Research Institute, San Francisco, CA
 
9:55 AM
191
Antitumor activity of the ribonucleotide reductase inhibitor triapine alone or in combination with paclitaxel
K. Ishiguro, Z. P. Lin, T. J. Rutherford and E. S. Ratner
Yale University School of Medicine, New Haven, CT
 
9:55 AM
192
Phase II trial of bevacizumab with carboplatin and dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer
N. D. Fleming1, R. L. Coleman1, C. S. Tung2, M. F. Munsell1 and A. K. Sood1
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2Baylor College of Medicine, Houston, TX
 
9:55 AM
193
Comprehensive health related quality of life profiling using a novel idiographic goal-oriented metric in patients with advanced malignancies: a pilot study
J. Y. Hou1, G. Kaur1, S. Goel1, M. Ghalib2, U. Shah2, M. Klobocista1, G. L. Goldberg1, B. D. Rapkin1 and N. S. Nevadunsky1
1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 2Montefiore Medical Center, New York, NY
 
9:55 AM
194
Uncertainty in self-reported responses to a symptoms questionnaire relevant to gynecologic oncology
L. A. Baldwin1, E. J. Pavlik2, D. Woolum2, E. Elliott2, C. Y. Chen3, J. Hoff2, J. Lefringhouse2, R. W. Miller1, C. P. Desimone1, F. R. Ueland1, R. Kryscio1 and J. R. Vannagell1
1University of Kentucky Medical Center, Lexington, KY, 2University of Kentucky, Lexington, KY, 3University of Kentucky College of Medicine, Lexington, KY
 
9:55 AM
195
A quality initiative to improve compliance with perioperative anticoagulation
E. Pelkofski1, L. A. Cantrell2, L. Duska2 and J. Rowlingson2
1University of Virginia Medical Center, Charlottesville, VA, 2University of Virginia School of Medicine, Charlottesville, VA
 
9:55 AM
196
Opioid risk screening in gynecologic oncology patients: a pilot study
E. Pelkofski1, W. D. Baker1, J. R. Te Paske1, L. Blackhall2 and L. A. Cantrell2
1University of Virginia Medical Center, Charlottesville, VA, 2University of Virginia School of Medicine, Charlottesville, VA
 
9:55 AM
197
Informed consent and patient satisfaction in gynecologic oncology: a pilot study
E. Pelkofski1, M. Pardo2, L. A. Cantrell2 and L. Duska2
1University of Virginia Medical Center, Charlottesville, VA, 2University of Virginia School of Medicine, Charlottesville, VA
 
9:55 AM
198
A comparison of epidural analgesia and patient controlled intravenous analgesia on postoperative pain control and recovery parameters in women undergoing laparotomy for gynecologic malignancy
K. Tucker, C. Murray-Krezan, C. Muller and T. Rutledge
University of New Mexico, Albuquerque, Albuquerque, NM
 
9:55 AM
199
Are hospital readmissions an accurate measure of quality cancer care in gynecologic oncology patients?
D. N. Pasko, J. D. Boone, E. D. Thomas, W. K. Huh, R. D. Alvarez, C. A. Leath III and J. M. Straughn Jr.
University of Alabama at Birmingham, Birmingham, AL
 
9:55 AM
200
Beyond fertility: the safety of ovarian preservation in women with complex endometrial hyperplasia with atypia
K. M. Anderson, N. R. Shah, M. A. Davis, L. M. Bean, C. C. Saenz, S. C. Plaxe and M. T. McHale
UCSD Rebecca and John Moores Cancer Center, La Jolla, CA
 
9:55 AM
201
Relationship of locus of control and depression to treatment adherence in gynecologic oncology patients
R. Viswanathan1, R. Rana1, Y. C. Lee2, I. Alagkiozidis2, M. Reinhardt1, A. Arain1, J. Tolentino2 and T. S. Pradhan3
1SUNY Downstate Medical Center, Brooklyn, NY, 2SUNY Downstate, Brooklyn, NY, 3New York Medical College, Valhalla, NY
 
9:55 AM
202
Limited training exposure in intraoperative radiation therapy (IORT) may result in omission of its use in treating locally advanced gynecologic malignancies
K. S. Grzankowski, J. B. Szender, S. B. Lele, K. O. Odunsi and P. J. Frederick
Roswell Park Cancer Institute, Buffalo, NY
 
9:55 AM
203
Predictors of 30-day readmission in gynecologic oncology
S. Uppal1, M. Stasenko1, K. McLean1, J. R. Liu2, C. M. Johnston2 and R. K. Reynolds2
1University of Michigan Health Systems, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI
 
9:55 AM
204
Caffeine intake and endometrial cancer risk in the PLCO cohort
F. W. Liu1,2, C. Galeone3, S. S. Buys4, L. Gren4, P. Boffetta5, C. La Vecchia6, Z. F. Zhang2 and M. Hashibe7
1University of California at Irvine Medical Center, Orange, CA, 2UCLA Fielding School of Public Health, Los Angeles, CA, 3Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy, 4University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, 5The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, 6University of Milan, Milan, Italy, 7University of Utah, Salt Lake City, UT
 
9:55 AM
205
Predictive model of conversion to laparotomy in minimally invasive surgery for endometrial cancer
C. E. Jung1, M. S. Hom2, M. R. Gualtieri3, S. C. D. Randazzo3, H. Kanao4, A. A. Yessaian5 and K. Matsuo3
1University of Southern California, Los Angeles, CA, 2Keck School of Medicine of USC, Los Angeles, CA, 3LAC+USC Medical Center, Los Angeles, CA, 4Cancer Institute Hospital, Tokyo, Japan, 5University of Southern California, Encino, CA
 
9:55 AM
206
Endometrial cancer survivor perspectives on weight loss and lifestyle modifications: a Uterine Cancer Action Network study
J. Tseng1, K. C. Long1, A. M. Jernigan1, R. Salani2, R. E. Bristow3 and A. Nickles Fader1
1Johns Hopkins Medical Institutions, Baltimore, MD, 2The Ohio State University, Columbus, OH, 3University of California, Irvine, Irvine, CA
 
9:55 AM
207
A comparison of progression free survival and postoperative outcomes for early stage endometrioid adenocarcinoma following robotic-assisted staging and open laparotomy
M. Ulm1, D. N. Ginn2, K. M. Reed1, T. Tillmanns3, A. C. ElNaggar4, S. J. Dedania1 and M. E. Reed3
1University of Tennessee Health Science Center, Memphis, TN, 2University of Louisville School of Medicine, Louisville, KY, 3West Clinic, Memphis, TN, 4The Ohio State University, Columbus, OH
 
9:55 AM
208
Outcomes in stage III endometrial cancer are similar for chemotherapy +/- radiation in low and high risk histology
F. J. Backes, C. Cosgrove, G. Agrawal, L. J. Copeland, D. M. O'Malley, R. Salani, D. E. Cohn and J. M. Fowler
The Ohio State University, James Cancer Hospital, Columbus, OH
 
9:55 AM
209
Correlation between type I uterine cancer and diet and lifestyle in US-born versus immigrant Asian subgroups
T. Tsuei1, K. Blansit2, A. B. Gardner2, R. A. Brooks1, S. M. Ueda1, D. S. Kapp3 and J. K. Chan4
1UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, 2Palo Alto Medical Foundation Research Institute, Palo Alto, CA, 3Stanford University, Stanford, CA, 4California Pacific & Palo Alto Medical Foundation / Sutter Research Institute, San Francisco, CA
 
9:55 AM
210
Lymph-vascular space invasion in uterine corpus cancer: what is its prognostic significance in the absence of lymph node metastases?
S. A. Neal1, W. A. Graybill1, E. Garrett-Mayer1, M. L. McDowell2, V. E. McLean3, C. H. Watson4 and W. T. Creasman1
1Medical University of South Carolina, Charleston, SC, 2Greenville Health System, Greenville, SC, 3University at Buffalo, Buffalo, NY, 4University of Tennessee Health Science Center, Memphis, TN
 
9:55 AM
211
Types of surgery for morbidly obese endometrial cancer patients in the US: how and where do we make the largest impact?
J. Fuh1, J. K. Chan2, K. Blansit3, A. B. Gardner3, L. M. Chen1, R. A. Brooks1, S. M. Ueda1, X. Yu4 and D. S. Kapp5
1UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, 2California Pacific & Palo Alto Medical Foundation / Sutter Research Institute, San Francisco, CA, 3Palo Alto Medical Foundation Research Institute, Palo Alto, CA, 4University of Memphis, Memphis, TN, 5Stanford University, Stanford, CA
 
9:55 AM
212
Differences in survival between clear cell uterine and ovarian carcinoma patients
I. Usach1, K. Blansit2, A. B. Gardner2, D. S. Kapp3, L. M. Chen1, S. M. Ueda1, R. A. Brooks1 and J. K. Chan4
1UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, 2Palo Alto Medical Foundation Research Institute, Palo Alto, CA, 3Stanford University, Stanford, CA, 4California Pacific & Palo Alto Medical Foundation / Sutter Research Institute, San Francisco, CA
 
9:55 AM
213
Significance of omentectomy during surgical staging for uterine serous carcinoma
N. Thomakos, I. Koutroumpa, S. P. Trachana, M. Sotiropoulou, D. Haidopoulos, C. Papadimitriou, A. Bamias, G. Vlachos and A. Rodolakis
Alexandra Hospital, University of Athens, Athens, Greece
 
9:55 AM
214
The impact of time between histologic diagnosis of endometrial cancer and surgical treatment on stage and survival
J. N. Sabourin and S. Glaze
University of Calgary Tom Baker Centre, Calgary, AB, Canada
 
9:55 AM
215
The effects of obesity on robotic-assisted pelvic and periaortic node sampling in endometrial cancer
K. M. Reed1, M. Ulm1, A. C. ElNaggar2, T. Tillmanns3 and M. E. Reed3
1University of Tennessee Health Science Center, Memphis, TN, 2The Ohio State University, Columbus, OH, 3West Clinic, Memphis, TN
 
9:55 AM
216
Is hypothyroidism a risk factor for types of uterine cancer?
C. C. Ward1, M. S. Shahin2 and M. I. Edelson2
1University of Iowa Hospitals and Clinics, Iowa City, IA, 2Hanjani Institute for Gynecologic Oncology, Abington Memorial Hospital, Abington, PA
 
9:55 AM
217
Longitudinal analysis of cancer-associated biomarkers within weight loss intervention for endometrial cancer survivors with obesity
A. F. Haggerty1, G. Raggio2, J. Spitzer1, J. Boyer3, D. B. Sarwer1, C. Chu4 and K. Allison1
1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania Health System, Philadelphia, PA, 3Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 4Fox Chase Cancer Center, Philadelphia, PA
 
9:55 AM
218
Operative outcomes for women undergoing robotic-assisted hysterectomy in the treatment of endometrial cancer: a Washington State population-based study, 2008-2011
T. L. Beck, M. A. Schiff, B. A. Goff and R. R. Urban
University of Washington Medical Center, Seattle, WA
 
9:55 AM
219
Trends in Treatment of Uterine Serous Cancer in the Medicare Population
J. A. Rauh-Hain1, S. C. Connor2, J. T. Clemmer1, O. W. Foley2, R. M. Clark1, T. R. Hall2, D. M. Boruta II1, J. O. Schorge1 and M. del Carmen1
1Massachusetts General Hospital/Harvard University, Boston, MA, 2Massachusetts General Hospital, Boston, MA
 
9:55 AM
220
Signs and symptoms of venous thromboembolism and survival outcome in endometrial cancer
K. Matsuo1, M. S. Hom2, M. D. Toboni2, J. J. Yeo3, C. S. Ghattas1 and L. D. Roman4
1LAC+USC Medical Center, Los Angeles, CA, 2Keck School of Medicine of USC, Los Angeles, CA, 3LAC+USC Medical Center - Women and Children's Hospital, Los Angeles, CA, 4LAC+USC Medical Center - Women and Children’s Hospital, Los Angeles, CA
 
9:55 AM
221
Contributing factors for menopausal symptoms after surgical staging for endometrial cancer
M. D. Toboni1, S. S. Cahoon2, M. R. Gualtieri3, K. Hasegawa4, D. Shoupe2, L. I. Muderspach2 and K. Matsuo3
1Keck School of Medicine of USC, Los Angeles, CA, 2University of Southern California, Los Angeles, CA, 3LAC+USC Medical Center, Los Angeles, CA, 4Saitama Medical University International Medical Center, Saitama, Japan
 
9:55 AM
222
Non-alcoholic fatty liver disease and risk of venous thromboembolism in endometrial cancer
K. Matsuo1, J. Garcia1, T. Miki2, N. Ushioda3, L. L. Brunette1, O. Matsuo4 and L. D. Roman5
1LAC+USC Medical Center, Los Angeles, CA, 2Keck School of Medicine of USC, Los Angeles, CA, 3Cancer Institute Hospital, Japan, Tokyo, Japan, 4Kinki University Faculty of Medicine, Osakasayama, Japan, 5LAC+USC Medical Center - Women and Children’s Hospital, Los Angeles, CA
 
9:55 AM
223
Outcomes of fertility-sparing treatment with progestin in patients with early-stage endometrial cancer or severe atypical hyperplasia: preliminary results of a phase II study in China
K. Shen
Peking Union Medical College Hospital, Beijing, China
 
9:55 AM
224
Impact of venous thromboembolism on mortality of elderly medicare patients with epithelial endometrial cancer
J. A. Rauh-Hain1, J. T. Clemmer1, A. Melamed2, E. Diver3, T. R. Hall3, R. M. Clark1, W. B. Growdon1, J. O. Schorge1, M. del Carmen3 and A. Goodman1
1Massachusetts General Hospital/Harvard University, Boston, MA, 2Brigham and Women's Hospital/Massachussets General Hospital, Boston, MA, 3Massachusetts General Hospital, Boston, MA
 
9:55 AM
225
Further stratification of subgroups with long term survival after recurrence in endometrial cancer
S. H. Shim1, D. Y. Kim2, D. S. Suh3, J. H. Kim3, Y. M. Kim3, Y. T. Kim3 and J. H. Nam3
1Konkuk University School of Medicine, Seoul, South Korea, 2ASAN Medical Center, Seoul, South Korea, 3University of Ulsan College of Medicine, ASAN Medical Center, Seoul, South Korea
 
9:55 AM
226
Sentinel lymph node mapping in women with high risk histology endometrial cancer
J. A. Ehrisman, A. A. Secord, A. Berchuck, P. S. Lee, N. Di Santo, F. A. Valea and L. J. Havrilesky
Duke University Medical Center, Durham, NC
 
9:55 AM
227
The role of cytoreductive surgery for recurrent endometrial cancer
S. H. Shim1, D. Y. Kim2, D. S. Suh2, J. H. Kim2, Y. M. Kim2, Y. T. Kim2 and J. H. Nam2
1Konkuk University School of Medicine, Seoul, South Korea, 2University of Ulsan College of Medicine, ASAN Medical Center, Seoul, South Korea
 
9:55 AM
228
Chemotherapy as adjuvant therapy for stage IA uterine papillary serous carcinoma
C. H. Watson1, M. Ulm1, T. Tillmanns2, M. E. Reed2 and K. M. Reed1
1University of Tennessee Health Science Center, Memphis, TN, 2West Clinic, Memphis, TN
 
9:55 AM
229
Population-level survival trends for uterine cancer
A. I. Tergas1, L. Chen2, C. Ananth2, J. Y. Hou1, W. M. Burke1, A. Neugut2, D. Hershman2 and J. D. Wright1
1NYP/Columbia University Medical Center, New York, NY, 2Columbia University College of Physicians and Surgeons, New York, NY
 
9:55 AM
230
Incidence and risk factors of lymphatic-related complications after robotic staging of endometrial cancer
A. Yuan1, P. Li2, D. Li2 and X. C. Zhou3
1University of Connecticut Health Center, Farmington, CT, 2Hartford Hospital, Hartford, CT, 3Hospital of Central Connecticut, New Britain, CT
 
9:55 AM
231
Efficacy of adjuvant chemotherapy in patients with stage IV endometrial cancer
C. L. Langstraat, J. N. Bakkum-Gamez, A. Mariani, A. Jatoi, M. McGree, A. L. Weaver, S. C. Dowdy and K. C. Podratz
Mayo Clinic, Rochester, MN
 
9:55 AM
232
Surgical outcomes of patients undergoing extrafascial hysterectomy following neoadjuvant high-dose rate brachytherapy for locally advanced endometrial cancer clinically extending to the cervix or parametria
M. M. Boisen, J. A. Vargo, S. Beriwal, P. Sukumvanich, A. B. Olawaiye, J. L. Kelley III, R. P. Edwards, M. Huang, M. B. Courtney-Brooks and J. T. Comerci
Magee-Womens Hospital of UPMC, Pittsburgh, PA
 
9:55 AM
233
Sentinel lymph node mapping in non-endometrioid endometrial cancer
X. B. Trinh1,2, O. Touhami2, J. Grégoire2, M. C. Renaud2, A. Sebastianelli2 and M. Plante3
1Antwerp University Hospital, Antwerp, Belgium, 2L'Hotel-Dieu de Quebec, Québec, QC, Canada, 3Laval University, L'Hotel-Dieu de Quebec, Quebec City, QC, Canada
 
9:55 AM
234
Novel sandwich therapy protocol supports role for concurrent chemoradiation in endometrial cancer
D. J. Wen1, H. E. Godoy2, L. M. Armao2, J. N. Barlin2, T. J. McElrath2, D. C. Kredentser2 and P. F. Timmins III2
1Albany Medical Center, Albany, NY, 2Women's Cancer Care Associates, Albany, NY
 
9:55 AM
235
Changing trends in the management of early stage endometrial cancer over the past decade: experience from a tertiary cancer center
J. A. Thomes Pepin, J. G. Ross, F. He and E. C. Rossi
Indiana University School of Medicine, Indianapolis, IN
 
9:55 AM
236
Role of surgical staging and adjuvant chemotherapy in the treatment of uterine carcinosarcoma
O. Cabrera1, C. Cho1, A. Dalmar1 and A. Mahdavi2
1Aurora Health Care, Milwaukee, WI, 2Aurora Health Care, West Allis, WI
 
9:55 AM
237
Integration of adjuvant chemotherapy in first-line management of uterine carcinosarcoma
K. N. Slaughter1, M. Rowland2, R. Bhattacharya3, K. N. Moore1 and D. S. McMeekin1
1The University of Oklahoma, Oklahoma City, OK, 2The University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK, 3Univertisy of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK
 
9:55 AM
238
Uterine sarcoma: ability of preoperative evaluation to identify malignancy and correct histology
S. K. Goodrich and J. Knight
The Cleveland Clinic Foundation, Cleveland, OH
 
9:55 AM
239
The comparison of the effect of all-trans retinoic acid, Methotrexate, Actinomycin D and combined chemotherapy on the different choriocarcinoma cell culture models
G. Sel1, M. Harma2, M. I. Harma2 and I. O. Tekin2
1Bartin Kadin Dogum ve Cocuk Hastaliklari Hastanesi, Bartın, Turkey, 2Bulent Ecevit University Medical Faculty, Zonguldak, Turkey
 
9:55 AM
240
Identifying potential therapeutics by molecular profiling of 136 cases of uterine clear cell carcinoma
N. L. Jones1, J. Xiu2, S. K. Reddy2, A. I. Tergas1, W. M. Burke1, J. D. Wright1 and J. Y. Hou1
1NYP/Columbia University Medical Center, New York, NY, 2Caris Life Sciences, Irving, TX
 
9:55 AM
241
Comparing vaginal sarcoma and carcinoma in the Surveillance, Epidemiology and End Results program, 1988 to 2010: an analysis of 4,062 patients
T. Ghezelayagh1,2, J. A. Rauh-Hain3 and W. B. Growdon3
1UCSF School of Medicine, San Francisco, CA, 2Harvard School of Public Health, Boston, MA, 3Massachusetts General Hospital/Harvard University, Boston, MA
 
9:55 AM
242
Management of stage I uterine leiomyosarcoma: is adjuvant chemotherapy beneficial?
J. Garcia1, T. Koru-Sengul2, F. Miao2 and J. De La Garza3
1LAC+USC Medical Center, Los Angeles, CA, 2University of Miami Miller School of Medicine, Miami, FL, 3University of Miami-Jackson Memorial Hospital, Miami, FL
 
9:55 AM
243
Surgical outcomes in patients undergoing radical vulvectomy
E. L. Barber, P. A. Gehrig and J. T. Soper
University of North Carolina at Chapel Hill, Chapel Hill, NC
 
9:55 AM
244
Sentinel lymph node mapping in patients with vulvar malignancies using indocyanine green and near-infrared imaging: preliminary detection rate experience
M. M. Leitao, E. Jewell, G. J. Gardner, O. Zivanovic, D. A. Levine, R. R. Barakat and N. R. Abu-Rustum
Memorial Sloan Kettering Cancer Center, New York, NY
 
9:55 AM
245
Gyn/Onc partnership with sarcoma center yields superior clinical trial enrollments for uterine leiomyosarcoma patients
S. S. Lange1, J. Liu2, A. R. Hagemann2, L. S. Massad2, D. A. Adkins3, P. H. Thaker2, K. C. Fuh4, M. A. Powell2, B. A. Van Tine3 and D. G. Mutch2
1Washington University, St. Louis, MO, 2Washington University School of Medicine, St. Louis, MO, 3Washington University School of Medicine, St Louis, MO, 4Stanford University, Stanford, CA
 
9:55 AM
246
Concordance of uterine sarcoma diagnosis based on method of preoperative evaluation
S. K. Goodrich, M. E. Buechel and J. Knight
The Cleveland Clinic Foundation, Cleveland, OH
 
9:55 AM
247
Factors associated with recurrence of vulvar squamous cell carcinoma
C. Hoppenot, A. P. Paintal, A. Rademaker, J. R. Lurain III and N. L. Neubauer
Northwestern University Feinberg School of Medicine, Chicago, IL
 
9:55 AM
248
Utility of intraoperative frozen section of the inguinofemoral sentinel lymph node in vulvar cancer: a retrospective cohort
A. C. ElNaggar1, C. Coffman2, E. Davis2, M. Duncan2 and M. E. Reed3
1The Ohio State University, James Cancer Hospital, Columbus, OH, 2University of Tennessee Health Science Center, Memphis, TN, 3West Clinic, Memphis, TN
 
9:55 AM
249
Evaluating risk factors for wound complications after radical vulvar surgery in a national cohort
N. A. Latif1, C. R. Washington2 and E. M. Ko3
1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania Medical Center, Philadelphia, PA, 3University of Pennsylvania, Penn Medicine, Philadelphia, PA
 
9:55 AM
250
Therapeutic dilemma: prognostic factors and outcome for patients with neuroendocrine tumors of the cervix
R. Abdallah1, Y. Xiong1, S. H. Bush2, H. S. Chon1, P. L. Judson Lancaster1, R. M. Wenham1, S. M. Apte1, J. M. Lancaster1 and M. M. K. Shahzad1
1H. Lee Moffitt Cancer Center, Tampa, FL, 2University of South Florida College of Medicine, Tampa, FL
 
9:55 AM
251
Comprehensive genetic testing: the next generation in an ovarian cancer risk assessment clinic
C. L. Walters Haygood, K. F. Handley, M. B. Farmer, R. D. Alvarez, C. A. Leath III and J. M. Estes
University of Alabama at Birmingham, Birmingham, AL
 
9:55 AM
252
Role of laparoscopy in determining optimal cytoreduction in patients with ovarian, fallopian tube and primary peritoneal cancer
V. Andikyan1, A. J. Kim2, T. Sierra2, H. F. Gretz III1, K. Zakashansky1, R. A. Segna3, A. M. Beddoe2, P. Dottino1, J. Mandeli2 and L. T. Chuang1
1Icahn School of Medicine at Mount Sinai, New York, NY, 2Mount Sinai School of Medicine, New York, NY, 3The Group for Women, New York, NY
 
9:55 AM
253
The impact of age on the risk of 30-day postoperative morbidity and mortality in patients undergoing surgery for ovarian cancer
H. Mahdi, R. DeBernardo and P. G. Rose
Cleveland Clinic, Cleveland, OH
 
9:55 AM
254
Access to high quality food and survival from ovarian cancer: an analysis of Cook County, Illinois
K. C. Brewer1, C. E. Peterson1, A. Beckmeyer-Borowko1, M. A. Otoo1, K. Hoskins2, F. Davis3 and C. E. Joslin1
1University of Illinois at Chicago School of Public Health, Chicago, IL, 2University of Illinois College of Medicine, Chicago, IL, 3University of Alberta School of Public Health, Edmonton, AB, Canada
 
9:55 AM
255
The effect of time on racial differences in ovarian cancer stage at diagnosis among cases identified through the National Cancer Database
A. Beckmeyer-Borowko1, K. C. Brewer1, C. E. Peterson1,2, M. A. Otoo1,3, F. Davis4, K. Hoskins3 and C. E. Joslin1,2,3
1University of Illinois at Chicago School of Public Health, Chicago, IL, 2University of Illinois at Chicago Cancer Center, Chicago, IL, 3University of Illinois College of Medicine, Chicago, IL, 4University of Alberta School of Public Health, Edmonton, AB, Canada
 
9:55 AM
256
Oral contraceptive use and reproductive characteristics affect survival in patients with epithelial ovarian cancer
N. V. Kolomeyevskaya, G. Zirpoli, M. Ruszczyk, K. S. Grzankowski, S. B. Lele, K. O. Odunsi and K. Moysich
Roswell Park Cancer Institute, Buffalo, NY
 
9:55 AM
257
Diagnostic value of combined 18F-FDG positron emission tomography/computed tomography in recurrent epithelial ovarian cancer with non-disseminated lesions: correlation with pathologic diagnosis of the secondary cytoreduction
P. S. Jung, S. W. Lee, J. Y. Park, D. S. Suh, D. Y. Kim, J. H. Kim, Y. M. Kim, Y. T. Kim and J. H. Nam
University of Ulsan College of Medicine, ASAN Medical Center, Seoul, South Korea
 
9:55 AM
258
Anti-NMDA receptor encephalitis: consider the ovaries
M. Zakhour1, A. E. Axtell1 and S. E. Lentz2
1Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, 2Kaiser Permanente Medical Group, Southern California, Los Angeles, CA
 
9:55 AM
259
The influence of staging system in pediatric ovarian cancer clinical outcomes
E. C. Rutledge, C. S. Tung, J. E. Dietrich, J. Muscal, M. E. Lopez and H. Sangi-Haghpeykar
Baylor College of Medicine, Houston, TX
 
9:55 AM
260
Transvaginal ultrasound-guided biopsy of adnexal masses as a useful diagnostic alternative replacing cytology or laparoscopy in advanced ovarian cancer patients
S. J. Chang1, T. W. Kong1, J. H. Son1, S. W. Kang2, J. Paek1, E. J. Lee2 and H. S. Ryu2
1Ajou University Hospital, Suwon, South Korea, 2Ajou University School of Medicine, Suwon, South Korea
 
9:55 AM
261
Perioperative β blockade improves overall survival in patients with ovarian cancer
E. L. Dickson1, J. Karnowski2, S. Saha3, C. Albertin4, A. McNally1 and A. N. Al-Niaimi3
1University of Minnesota, Minneapolis, MN, 2University of Wisconsin & Medical College of Wisconsin, Milwaukee, WI, 3University of Wisconsin School of Medicine and Public Health, Madison, WI, 4University of Minnesota Medical Center, Minneapolis, MN
 
9:55 AM
262
Choice of adjuvant chemotherapy following neoadjuvant carboplatin/paclitaxel and delayed primary debulking
D. M. Roque1, C. L. Schwab2, O. Goloubeva1, D. P. English2, J. D. Black2, D. A. Silasi2, M. Azodi2, T. J. Rutherford2, A. Santin2, P. E. Schwartz2 and E. S. Ratner2
1University of Maryland School of Medicine, Baltimore, MD, 2Yale University School of Medicine, New Haven, CT
 
9:55 AM
263
Trainee participation in surgery for ovarian cancer: impact on patient outcomes
E. L. Barber, P. A. Gehrig, V. L. Bae-Jump, W. R. Brewster, L. Van Le and K. H. Kim
University of North Carolina at Chapel Hill, Chapel Hill, NC
 
9:55 AM
264
The impact of blood transfusion on tumor recurrence and survival in patients with epithelial ovarian cancer
M. E. McDonald, A. o'Shea, H. D. Reyes, A. Button and M. J. Goodheart
University of Iowa Hospitals and Clinics, Iowa City, IA
 
9:55 AM
265
Pathologic assessment of response to neoadjuvant chemotherapy in ovarian cancer: correlation with survival
S. K. Goodrich, B. Nutter and H. Mahdi
Cleveland Clinic, Cleveland, OH
 
9:55 AM
266
Accuracy of frozen section in the diagnosis of mucinous ovarian tumors
A. Tranoulis1, N. Thomakos2, D. Haidopoulos2, M. Sotiropoulou2, N. Kathopoulis1, M. Davidovic-Grigoraki1, C. Papadimitriou2, A. Bamias2, G. Vlachos2 and A. Rodolakis2
1University of Athens School of Medicine, Alexandra Hospital, Athens, Greece, 2Alexandra Hospital, University of Athens, Athens, Greece
 
9:55 AM
267
IL-6, VTE and ovarian clear cell carcinoma: a dangerous triad
K. Matsuo1, K. Hasegawa2, K. Yoshino3, R. Murakami4, T. Hisamatsu5, Y. Ikeda6, T. Enomoto7, L. D. Roman8, C. Fotopoulou9 and A. K. Sood5
1LAC+USC Medical Center, Los Angeles, CA, 2Saitama Medical University International Medical Center, Saitama, Japan, 3Osaka University, Suita, Japan, 4Kyoto University Graduate School of Medicine, Kyoto, Japan, 5The University of Texas MD Anderson Cancer Center, Houston, TX, 6The Tokyo University Faculty of Medicine, Tokyo, Japan, 7Niigata University Graduate School of Medicine, Niigata, Japan, 8LAC+USC Medical Center - Women and Children’s Hospital, Los Angeles, CA, 9Imperial College London, London, United Kingdom
 
9:55 AM
268
Primary debulking surgery and neo-adjuvant chemotherapy in the Medicare population: an analysis of cost of care
G. K. Forde1, J. Chang2, A. Ziogas2, K. S. Tewari3 and R. E. Bristow2
1University of California at Irvine Medical Center, Orange, CA, 2University of California, Irvine, Irvine, CA, 3UC Irvine Medical Center, Orange, CA
 
9:55 AM
269
Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared to fallopian tube cancer
J. A. Rauh-Hain1, O. W. Foley2, R. M. Clark1, R. Vargas3, E. M. Hinchcliff4, K. M. Esselen4, N. S. Horowitz5 and M. del Carmen1
1Massachusetts General Hospital/Harvard University, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital/Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital/Harvard University, Boston, MA, 5Harvard University, Boston, MA
 
9:55 AM
270
Investigating the metabolic relationship between ovarian cancer cells and adipocytes: the role of fatty acid beta-oxidation
K. J. Hansen1 and B. Van Houten2
1Magee-Womens Hospital of UPMC, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA
 
9:55 AM
271
Integrated network analysis of miRNA-mRNA interactions in ovarian cancer outcomes
A. Lee1, J. L. Lovecchio2, J. Parasmeswaran3, I. Shapira4, M. Oswald1, A. W. Menzin2, J. S. Whyte2, L. Dos Santos2, S. Liang5, T. Bhuiya6, P. Gregersen1, C. Mason1 and M. Keogh1
1Feinstein Institute for Medical Research, Manhasset, NY, 2Hofstra - North Shore Long Island Jewish School of Medicine, Manhasset, NY, 3Yale University School of Medicine, New Haven, CT, 4Jacobi Medical Center, Bronx, NY, 5North Shore - LIJ Health System, Smithtown, NY, 6North Shore - LIJ Health System, Manhasset, NY
 
9:55 AM
272
The significance of paracardiac lymph-node enlargement in patients with newly diagnosed ovarian cancer
R. Eitan1, A. Aviram2, G. Sabah2, H. Levavi2 and O. Raban2
1Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Petah Tikva, Israel, 2Rabin Medical Center, Tel Aviv University, Petah Tikva, Israel
 
9:55 AM
273
Findings at laparoscopy, not debulking status, are associated with survival in advanced stage ovarian cancer after neoadjuvant chemotherapy
B. A. Davidson1, D. B. Mannschreck2, G. Broadwater2, M. Lopez-Acevedo2, P. S. Lee2, L. J. Havrilesky2, F. A. Valea2, A. Berchuck2 and A. A. Secord2
1Duke University School of Medicine, Durham, NC, 2Duke University Medical Center, Durham, NC
 
9:55 AM
274
Predicting overall survival in patients with ovarian cancer: a new clinical model
D. D. Luvero, F. F. Plotti, G. Scaletta, S. Capriglione, R. Ricciardi and R. Angioli
University Campus Bio-Medico of Rome, Rome, Italy
 
9:55 AM
275
Secular trends in relative survival for ovarian cancer
J. D. Wright, L. Chen, C. Ananth, A. I. Tergas, J. Y. Hou, W. M. Burke, A. Neugut and D. Hershman
Columbia University College of Physicians and Surgeons, New York, NY
 
9:55 AM
276
Peritoneal vascular cell adhesion molecule 1 (VCAM-1) is a marker of response to therapy and overall survival in epithelial ovarian cancer (EOC)
J. M. Scalici1, S. Arapovic2, E. Saks2, K. A. Atkins2, G. Petroni3, L. Duska4 and J. K. Slack-Davis3
1University of South Alabama-Mitchell Cancer Institute, Mobile, AL, 2University of Virginia Medical Center, Charlottesville, VA, 3University of Virginia, Charlottesville, VA, 4University of Virginia School of Medicine, Charlottesville, VA
 
9:55 AM
277
Does performance of omentectomy in epithelial ovarian cancer affect survival? An analysis of the SEER database
L. McNally1,2, N. N. H. Teng3, D. S. Kapp1 and A. K. Karam4
1Stanford University, Stanford, CA, 2University of California, San Francisco, San Francisco, CA, 3Stanford University Medical Center, Stanford, CA, 4Stanford Hospital and Clinics, Stanford, CA
 
9:55 AM
278
Does digoxin improve ovarian cancer survival? A SEER-Medicare database analysis
T. J. Vogel1, C. Jeon2, B. Y. Karlan2 and C. Walsh2
1Women’s Cancer Program/ Cedars-Sinai Medical Center, Los Angeles, CA, 2Cedars-Sinai Medical Center, Los Angeles, CA
 
9:55 AM
279
Cytoreductive surgery (CRS) and HIPEC in recurrent platinum resistant ovarian cancer
C. K. Brown1, S. Williams1, L. McNutt1, S. Beilick1, R. Flynn1, D. Litvack1, H. Huss1, A. R. Nair2 and G. Del Priore3,4
1Cancer Treatment Centers of America, Boca Raton, FL, 2Texas Tech University Health Sciences Center, Lubbock, TX, 3Morehouse School of Medicine, Atlanta, GA, 4Cancer Treatment Centers of America, Newnan, GA
 
9:55 AM
280
The increase in hospital charges associated with ovarian cancer treatment: an economic analysis of 83,552 patients
A. B. Gardner1, D. S. Kapp2, N. Young-Lin3, E. J. Simons3, X. Yu4 and J. K. Chan5
1Palo Alto Medical Foundation Research Institute, Palo Alto, CA, 2Stanford University, Stanford, CA, 3UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, 4University of Memphis, Memphis, TN, 5California Pacific & Palo Alto Medical Foundation / Sutter Research Institute, San Francisco, CA
 
9:55 AM
281
The significance of preoperative carbohydrate antigen (CA125) and human epididymis protein 4(HE4) serum level to predict pelvic or paraaortic lymph node metastasis in epithelial ovarian cancer patients
A. Soochit
Sun Yat-Sen University, Cancer Center, Guangzhou, China
 
9:55 AM
282
Feasibility of tertiary and quaternary cytoreduction in recurrent epithelial ovarian cancer
F. Fanfani1, A. Fagotti2, V. Gallotta3, P. A. Margariti3, G. Monterossi1, S. Restaino4, V. Chiantera3, E. Shallayeva3 and G. Scambia1
1Catholic University Sacred Heart of Rome, Rome, Italy, 2St. Maria Hospital, University of Perugia, Terni, Italy, 3Catholic University of the Sacred Heart, Milan, Italy, 4Institute for Maternal and Child Health – IRCCS “Burlo Garofolo”, Trieste, Italy
 
9:55 AM
283
Heterogeneity of energy dynamics in ovarian cancer cell lines
R. Rattan1, J. Chhina1, S. Dar1, S. Hensley Alford1, M. Deshpande2, N. Rasool1, S. Giri1 and A. R. Munkarah1
1Henry Ford Health System, Detroit, MI, 2Henry Ford Hospital, Detroit, MI
 
9:55 AM
284
Prognostic factors after secondary cytoreducton in epithelial ovarian cancer
G. Baiocchi, A. A. B. A. Costa, C. V. V. Amorim, H. Mantoan, A. Saito, L. Y. Kumagai, C. Faloppa, L. Badiglian-Filho, S. M. Sanches and A. P. G. Guimaraes
A.C. Camargo Cancer Center, São Paulo, Brazil
 
9:55 AM
285
Comparative proteomics of ovarian cancer spheroid formation reveals an increased expression of calcium-activated chloride channel regulator 1
N. Musrap1, A. Tuccitto2, G. Karagiannis3, P. Saraon4 and E. P. Diamandis5
1Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Mount Sinai Hosptial, Toronto, ON, Canada, 4Mount Sinai Hospital, Toronto, ON, Canada, 5University Health Network, Toronto, ON, Canada
 
9:55 AM
286
Unique molecular portraits of ovarian cancer: implications for prognostics and targeted therapeutics
B. R. Khulpateea1, D. Marchion2, Y. Xiong2, C. McClung1, S. H. Bush3, I. Ramirez1, S. M. Apte2, P. Judson1, A. Hakam2 and J. M. Lancaster2
1H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 2H. Lee Moffitt Cancer Center, Tampa, FL, 3University of South Florida College of Medicine, Tampa, FL
 
9:55 AM
287
Fallopian tube detection with transvaginal ultrasonography
J. Lefringhouse1, E. J. Pavlik1, E. Neward2, F. R. Ueland2, L. A. Baldwin2, R. W. Miller2, C. P. Desimone2 and J. R. Vannagell2
1University of Kentucky, Lexington, KY, 2University of Kentucky Medical Center, Lexington, KY
 
9:55 AM
288
Evaluating anti-cancer activity of a novel p53 derived peptide against multidrug resistant ovarian cancer
M. F. Shaikh1, D. Zimmerman1, K. Davitt1, E. M. Gleeson1, P. Love1, B. D. Babcock1, M. R. Pincus2, W. B. Bowne1, S. D. Richard1 and A. R. Desai1
1Hahnemann University Hospital/Drexel University College of Medicine, Philadelphia, PA, 2SUNY Downstate, Brooklyn, NY
 
9:55 AM
289
Neoadjuvant chemotherapy reduces operative morbidity without effecting time to recurrence in advanced stage epithelial ovarian cancer
S. E. Taylor, J. Berger, K. Johnson, M. M. Boisen, M. B. Courtney-Brooks, P. Sukumvanich, J. L. Kelley III and M. Huang
Magee-Womens Hospital of UPMC, Pittsburgh, PA
 
9:55 AM
290
Time to chemotherapy following surgical cytoreduction for epithelial ovarian cancer: does neoadjuvant chemotherapy make a difference?
M. M. Boisen, J. Berger, J. Phillips, S. E. Taylor, A. Peters, J. T. Comerci, R. P. Edwards, J. L. Kelley III, P. Sukumvanich and M. Huang
Magee-Womens Hospital of UPMC, Pittsburgh, PA
 
9:55 AM
291
Visceral adiposity associated with increased risk of death from ovarian cancer
Y. Zhang, P. Allen, L. A. Meyer, C. C. L. Sun, K. M. Basen-Engquist, K. H. Lu and A. H. Klopp
The University of Texas MD Anderson Cancer Center, Houston, TX
 
9:55 AM
292
Combined preoperative and extended pharmacologic venous thromboembolic prophylaxis in patient undergoing surgery for advanced adnexal malignancies
Y. Sonoda1, J. E. Wolford2, A. Gojayev1, M. M. Leitao1, E. Jewell1, G. J. Gardner1, C. L. Brown1, O. Zivanovic1, D. A. Levine1, N. R. Abu-Rustum1, R. R. Barakat1, D. S. Chi1 and S. J. Lee1
1Memorial Sloan Kettering Cancer Center, New York, NY, 2UC Irvine Medical Center, Orange, CA
 
9:55 AM
293
Ignoring benign hysterectomy leads to biased results in endometrial cancer risk factor studies
R. L. Dood Jr.1, S. Boudhar2, E. M. Ko3, B. L. Strom2 and M. D. Sammel2
1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 3University of Pennsylvania, Penn Medicine, Philadelphia, PA
 
9:55 AM
294
Promoting community-based lifestyle modification and weight management in African American endometrial cancer survivors and their female social network
N. K. Lee, K. A. Mills, P. S. Lyman, D. R. Young, S. Orzalli, S. D. Yamada, M. E. Tenney and M. Gilliam
University of Chicago, Chicago, IL
 
9:55 AM
295
Targeted ovarian cancer education for Hispanic women: a pilot program in Arizona
M. P. Schlumbrecht1, R. Yarian1, C. Niven2, K. Salmon1 and D. K. Singh3
1Banner MD Anderson Cancer Center, Gilbert, AZ, 2Mesa Public Schools, Mesa, AZ, 3Mid Atlantic Permanente Medical Group, Rockville, MD
 
9:55 AM
296
Endometrial cancer survivors may serve as ambassadors for positive health behavioral change
L. H. Clark1, E. M. Ko2, A. Kernodle3, A. Harris4, D. T. Moore1, P. A. Gehrig1 and V. L. Bae-Jump1
1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of Pennsylvania, Penn Medicine, Philadelphia, PA, 3University of North Carolina School of Medicine, Chapel Hill, NC, 4University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
 
9:55 AM
297
The teachable moment: physician counseling and behavioral changes following a diagnosis of endometrial cancer
L. H. Clark1, E. M. Ko2, A. Kernodle3, A. Harris4, D. T. Moore1, P. A. Gehrig1 and V. L. Bae-Jump1
1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of Pennsylvania, Penn Medicine, Philadelphia, PA, 3University of North Carolina School of Medicine, Chapel Hill, NC, 4University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
 
9:55 AM
298
Epidemiologic characteristics of uterine corpus cancer in Korean women
J. M. Lee1 and K. D. Ki2
1Kyung Hee University, Seoul, South Korea, 2Kyung Hee University Hospital at Gangdong, Seoul, South Korea
 
9:55 AM
299
The preoperative experience for public hospital patients: do structural barriers widen the gap?
H. A. Moss, M. K. Frey, F. Musa, G. David-West, J. Y. Chern, L. R. Boyd and J. P. Curtin
New York University School of Medicine, New York, NY
 
9:55 AM
300
A systematic review of radiotherapy resources in low and middle income countries
S. Grover1, M. J. Xu2, A. Yeager2, D. Rodin3, S. Chackungal4, M. Mangaali2, L. Rosman5, R. S. Groen5 and A. I. Tergas6
1University of Pennsylvania, Philadelphia, PA, 2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 3University of Toronto, Toronto, ON, Canada, 4Schulich School of Medicine and Dentistry, London, ON, Canada, 5Johns Hopkins School of Medicine, Baltimore, MD, 6Columbia University College of Physicians and Surgeons, New York, NY
 
9:55 AM
301
Are ASCCP guidelines for follow up of women with positive LEEP margins sufficient for clinical practice?
B. Lees, E. D. Thomas, J. D. Boone, S. Bae and M. Khan
University of Alabama at Birmingham, Birmingham, AL
 
9:55 AM
302
Outcomes for patients with advanced epithelial ovarian cancer treated with adjuvant chemotherapy at a regional network facility compared to the central campus
R. S. Suidan1, G. J. Gardner1, S. M. Lichtman2, P. B. Bach2, E. Jewell1, N. E. Mills2, T. A. Troso-Sandoval2, M. Gorsky2, C. L. Brown1 and R. R. Barakat1
1Memorial Sloan Kettering Cancer Center, New York, NY, 2Memorial Sloan-Kettering Cancer Center, New York, NY
 
9:55 AM
303
Factors associated with low educational background in uterine cancer patients
K. M. Shields1, L. Willmott2, J. H. Farley2, B. J. Monk3 and D. Chase4
1Maricopia Medical Center, Phoenix, AZ, 2St. Joseph's Hospital and Medical Center, Phoenix, AZ, 3University of Arizona Cancer Center, Phoenix, AZ, 4St. Joseph Hospital and Medical Center, Phoenix, AZ
 
9:55 AM
304
Internet search activity for cervical cancer (CxCa) correlates with international population risk
T. R. K. Korenaga1, K. K. Ward2, M. T. McHale1, C. C. Saenz1 and S. C. Plaxe1
1UCSD Rebecca and John Moores Cancer Center, La Jolla, CA, 2University of Florida College of Medicine-Jacksonville, Jacksonville, FL
 
9:55 AM
305
Prevalence of sexual dysfunction in women diagnosed with gynecologic malignancy
C. E. Bretschneider1, K. M. Doll1,2, J. T. Bensen2, P. A. Gehrig1,2, J. M. Wu1 and E. J. Geller1
1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
 
9:55 AM
306
A replicable clinical and research program to optimize sexual function outcomes for women with gynecologic and other cancers
J. Sobecki-Rausch1, E. Abrahmsohn2, S. Baron1, J. Florendo3, D. M. Kushner4, A. Rodolakis5, S. D. Yamada2 and S. T. Lindau2
1Northwestern University Feinberg School of Medicine, Chicago, IL, 2University of Chicago, Chicago, IL, 3Florendo Physical Therapy, Chicago, IL, 4University of Wisconsin School of Medicine and Public Health, Madison, WI, 5Alexandra Hospital, University of Athens, Athens, Greece
 
9:55 AM
307
Association of demographic and socio-economic factors in palliative care and the choice for hospice
S. R. Pierce, J. E. Stine, K. M. Doll, S. A. Sullivan, P. A. Gehrig, L. Hanson and K. H. Kim
University of North Carolina at Chapel Hill, Chapel Hill, NC
 
9:55 AM
308
Anxiety in patients undergoing ovarian cancer screening before and after in-office evaluation
S. Farag1, M. Chu2, L. D. Nguyen1, V. Andikyan3, E. B. Pereira1, E. L. Moshier1, S. Wilson1, S. Vaidya1 and D. A. Fishman1
1Mount Sinai School of Medicine, New York, NY, 2SUNY-Downstate, Brooklyn, NY, 3Icahn School of Medicine at Mount Sinai, New York, NY
 
9:55 AM
309
Comparison of quality of life after secondary cytoreductive surgery (SCS) ± HIPEC in recurrent ovarian cancer
M. Petrillo1, B. Costantini1, S. Cianci1, C. Ronsini1, F. Cosentino1, E. Shallayeva1, G. Scambia1 and A. Fagotti2
1Catholic University of the Sacred Heart, Milan, Italy, 2Catholic University of the Sacred Heart, Rome, Italy
 
9:55 AM
310
Program evaluation of a female sexual medicine and women's health program
J. Carter, B. Seidel, C. Stabile, R. E. Baser, A. Eaton, S. Benfante, A. R. Gunn, S. Goldfarb and D. J. Goldfrank
Memorial Sloan Kettering Cancer Center, New York, NY
 
9:55 AM
311
The effect of radical gynecologic surgery on urinary incontinence
T. T. Ilhan1, A. K. Kebapcilar2, B. B. B. Bakbak2, T. I. Ilhan3, S. A. Yilmaz4, T. C. Cakir2 and C. Celik5
1Selcuk University Medicine Faculty, Konya, Turkey, 2university of selcuk, Konya, Turkey, 3Beyhekim state hospital, Konya, Turkey, 4Selçuk University Medicine Faculty, Konya, Turkey, 5Selçuk University, Konya, Turkey
 
9:55 AM
312
Prospective correlation of multinational association for supportive care in cancer risk index score with outcomes in neutropenic fever
C. C. Gunderson1, B. K. Erickson2, I. Wilkinson-Ryan3, K. M. Doll4, B. White5, S. Vesely1, C. A. Leath III2, L. S. Massad3, P. A. Gehrig4 and K. N. Moore1
1The University of Oklahoma, Oklahoma City, OK, 2University of Alabama at Birmingham, Birmingham, AL, 3Washington University School of Medicine, St. Louis, MO, 4University of North Carolina at Chapel Hill, Chapel Hill, NC, 5University of North Carolina Hospitals, Chapel Hill, NC
 
9:55 AM
313
Ultrasound-guided intranodal lymphangiography with embolization: a novel technique to treat chylous ascites after retroperitoneal lymphadenectomy in gynecologic cancer
T. W. Kong1, J. Kim2, J. H. Son1, S. W. Kang2, S. J. Chang1, J. H. Won2 and H. S. Ryu2
1Ajou University Hospital, Suwon, South Korea, 2Ajou University School of Medicine, Suwon, South Korea
 
9:55 AM
314
The role of naturopathic doctors and supplement use in oncology patients
S. W. D. Sahadevan, T. Lawson, N. Dhillon and G. Del Priore
Cancer Treatment Centers of America, Newnan, GA
 
9:55 AM
315
Cost-effectiveness analysis of robotically assisted radical hysterectomy for newly diagnosed uterine cervical cancer
M. M. Leitao, R. Keller, V. Sioulas, W. R. Narain, D. Boccamazzo, N. Barrow, D. S. Chi, N. R. Abu-Rustum, Y. Sonoda, C. L. Brown, E. Jewell, R. R. Barakat and G. J. Gardner
Memorial Sloan Kettering Cancer Center, New York, NY
 
9:55 AM
316
Comparison of preemptive transversus abdominis plane block versus local injection of analgesic for postoperative pain control in minimally invasive gynecologic surgery
E. C. Liberman1, T. R. Denehy2, J. R. Schortz3 and A. R. Van Arsdale1
1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 2Gynecologic Cancer and Pelvic Surgery, West Orange, NJ, 3Saint Barnabas Medical Center, Livingston, NJ
 
9:55 AM
317
Laparoscopic comprehensive therapeutic pelvic to infrarenal lymphadenectomy
K. A. O'Hanlan1, M. Chivukula2, M. S. Sten1, N. N. Ford1 and S. P. McCutcheon1
1Laparoscopic Institute for Gynecology and Oncology, Portola Valley, CA, 2Sequoia Hospital, Redwood City, CA
 
9:55 AM
318
Minimally invasive surgery versus laparotomy for interval cytoreduction after neoadjuvant chemotherapy for ovarian cancer
K. Mori1, C. H. Hoppenot1, I. Helenowski1, E. Berry2, J. R. Lurain III3 and N. L. Neubauer3
1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Prentice Women's Hospital, Chicago, IL, 3Northwestern University Feinberg School of Medicine, Chicago, IL
 
9:55 AM
319
Laparoscopic retroperitoneal therapeutic pelvic to infrarenal lymphadenectomy
K. A. O'Hanlan1, M. S. Sten1, N. N. Ford1, M. Chivukula2 and S. P. McCutcheon1
1Laparoscopic Institute for Gynecology and Oncology, Portola Valley, CA, 2Sequoia Hospital, Redwood City, CA
 
9:55 AM
320
Clinical outcomes of hysterectomies for benign and malignant etiologies using the NSQIP database
E. Chalas1, H. Chen1, E. A. Jimenez1, J. A. Villella1, K. C. Chan1, M. Fazzari1 and H. Toskos2
1Winthrop University Hospital, Mineola, NY, 2Stony Brook University, Stony Brook, NY
 
9:55 AM
321
Fluorescent illumination of the genitourinary tract in laparoscopic surgery: a novel in vivo imaging technique
M. L. Korb1, J. D. Boone2, J. M. Warram3, T. K. Chung1, K. I. Bland1, E. L. Rosenthal1 and W. K. Huh2
1University of Alabama Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3The University of Alabama at Birmingham, Birmingham, AL
 
9:55 AM
322
The effect of gynecologic oncology training on surgical outcomes of radical hysterectomy
N. A. Latif1, R. A. Burger1, M. A. Morgan1 and E. M. Ko2
1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Penn Medicine, Philadelphia, PA
 
9:55 AM
323
The impact of robotic surgical training in an obstetrics and gynecology residency training curriculum
M. Renz1, E. C. Liberman2, Y. S. Kuo2, G. L. Goldberg2 and N. S. Nevadunsky2
1Marine Biological Laboratory, Woods Hole, MA, 2Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
 
9:55 AM
324
Outcomes of robotic secondary cytoreductive surgery for recurrent ovarian carcinoma
J. P. Diaz1, A. E. Garcia-Soto2, M. Barrios3, E. D. Schroeder1, R. A. Estape1, K. Lopez1 and R. E. Estape4
1South Miami Gynecologic Oncology Group, Miami, FL, 2University of Miami Jackson Memorial Hospital, Miami, FL, 3University of Miami School of Medicine, Miami, FL, 4South Miami Hospital, Miami, FL
 
9:55 AM
325
Safety and efficacy of robotic cytoreductive surgery in the management of recurrent ovarian carcinoma
J. P. Diaz1, E. D. Schroeder1, A. E. Garcia-Soto2, K. Lopez1, M. Barrios3, R. A. Estape1 and R. E. Estape4
1South Miami Gynecologic Oncology Group, Miami, FL, 2University of Miami Jackson Memorial Hospital, Miami, FL, 3University of Miami School of Medicine, Miami, FL, 4South Miami Hospital, Miami, FL
 
9:55 AM
326
A novel orthotopic mouse model of epithelial ovarian carcinoma demonstrating progression from early stage disease to carcinomatosis in both immune-competent and immune-deficient models
J. Berger1, T. L. Beck2, P. Mital3, E. Elishaev1, M. Sukhwani3, S. Oesterreich1, A. Vlad1, T. C. Krivak4, J. L. Kelley III1 and K. Orwig1
1Magee-Womens Hospital of UPMC, Pittsburgh, PA, 2University of Washington Medical Center, Seattle, WA, 3Magee-Womens Research Institute and Foundation, Pittsburgh, PA, 4Western Pennsylvania Hospital, Pittsburgh, PA
 
9:55 AM
327
The interaction between glutamine and the mTOR pathway in ovarian cancer cell proliferation and metabolism
D. R. Roque, L. Yuan, W. Z. Wysham, C. Zhou and V. L. Bae-Jump
University of North Carolina at Chapel Hill, Chapel Hill, NC
 
9:55 AM
328
Utilizing camelid-derived single domain antibodies to enhance immunotherapy of ovarian cancer
E. A. van Erp1, L. N. Kaliberova1, S. A. Kaliberov1, E. D. Thomas2, K. S. Bevis2, R. D. Alvarez2 and D. T. Curiel3
1Washington University School of Medicine, St Louis, MO, 2University of Alabama at Birmingham, Birmingham, AL, 3Washington University School of Medicine, St. Louis, MO
 
9:55 AM
329
Role of PDZ binding kinase (PBK) associated to guanylate binding protein 1 (GBP1) for drug resistance in ovarian cancer
L. Sevciunaite1, M. Petrillo2,3, L. Petrella1, C. Baranello1, M. Fanelli1, A. Camperchioli1, M. Mariani4, A. Fagotti5, G. Scambia2 and C. Ferlini6
1Jean Paul II Research Foundation, Campobasso, Italy, 2Catholic University of the Sacred Heart, Milan, Italy, 3St. Maria Hospital - University of Perugia, Terni, Italy, 4Western Connecticut Health Network/Danbury Hospital, Danbury, CT, 5St. Maria Hospital, University of Perugia, Terni, Italy, 6Western Connecticut Health Network/Danbury Hospital, Danbury, CT
 
9:55 AM
330
The ratio between type 1 and type 2 tumor-associated macrophages predicts prognosis in patients with locally advanced cervical cancer receiving chemoradiation
M. Petrillo1, G. Zannoni1, E. Martinelli1, L. Pedone Anchora1, G. Ferrandina1, G. Tropeano1, A. Fagotti2 and G. Scambia1
1Catholic University of the Sacred Heart, Milan, Italy, 2St. Maria Hospital, University of Perugia, Terni, Italy
 
9:55 AM
331
c-MET as a Potential Target in Ovarian Clear-Cell Carcinoma
A. Yoon1, J. W. Lee2, Y. Y. Lee1, T. J. Kim2, W. Y. Kim3, B. G. Kim2, D. S. Bae2 and M. K. Kim4
1Samsung Medical Center, Seoul, South Korea, 2Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 3Kangbuk Samsung Hospital, Seoul, South Korea, 4Sungkyunkwan University School of Medicine, Changwon-Si, South Korea
 
9:55 AM
332
Antibody fragments targeting the tumor marker mesothelin selectively deliver TRAIL therapeutics and cause efficient ovarian cancer cell death
L. M. Kuroki1, K. Tatzel1, M. A. Powell1, D. G. Mutch1, A. B. Dietz2, W. Hawkins1 and D. Spitzer1
1Washington University School of Medicine, St. Louis, MO, 2Mayo Clinic, Rochester, MN
 
9:55 AM
333
The role of Sox17 in endometrial gland formation and carcinogenesis
A. Guimaraes-Young, T. Neff, A. Dupuy and M. J. Goodheart
University of Iowa Hospitals and Clinics, Iowa City, IA
 
9:55 AM
334
Proteomic analysis of cisplatin resistance in the ovarian cancer line CaOv3
E. A. Dubil1, P. N. Teng2, G. Wang2, K. A. Conrads2, B. L. Hood2, G. L. Maxwell3, C. A. Hamilton1 and T. P. Conrads2
1Walter Reed National Military Medical Center, Bethesda, MD, 2Gynecologic Cancer Center of Excellence, Annandale, VA, 3Inova Fairfax Hospital, Falls Church, VA
 
9:55 AM
335
Integrated genomic analysis of STIC-associated high-grade serous carcinoma
J. A. Ducie1, F. Bogomolniy1, F. Dao1, N. Olvera2, P. Shaw3, I. M. Shih4, R. J. Kurman5, R. A. Soslow1, L. Cope4 and D. A. Levine1
1Memorial Sloan Kettering Cancer Center, New York, NY, 2Memorial Sloan-Kettering Cancer Center, New York, NY, 3University of Toronto, Toronto, ON, Canada, 4Johns Hopkins School of Medicine, Baltimore, MD, 5Johns Hopkins Medical Institutions, Baltimore, MD
 
9:55 AM
336
Different microbial communities of malignant and benign endometrium
B. K. Erickson, A. Subramaniam, R. Kumar, W. K. Huh and C. Morrow
University of Alabama at Birmingham, Birmingham, AL
 
9:55 AM
337
Comparison of MISR2 expression in patient and successive passages of patient-derived xenografts of ovarian cancer
S. Gill1, Q. Zhang1, P. Haluska Jr.1, J. N. Bakkum-Gamez2, B. A. Cliby2 and S. J. Weroha2
1Mayo Clinic College of Medicine, Rochester, MN, 2Mayo Clinic, Rochester, MN
 
9:55 AM
338
A prospective phase 0 study on the effects of anesthetic selection on serum miRNA profiles during primary cytoreductive surgery for suspected ovarian cancer
K. M. Elias1,2,3,4, A. Fusco5, S. Kang1, D. Michaud1, R. S. Berkowitz1,2,3, N. S. Horowitz1,2,3 and G. Frendl1,2
1Brigham and Women's Hospital, Boston, MA, 2Harvard Medical School, Boston, MA, 3Dana-Farber Cancer Institute, Boston, MA, 4Surgical ICU Translational Research Center, Boston, MA, 5Firefly BioWorks, Inc., Cambridge, MA
 
9:55 AM
339
Sperm protein 17 is a novel biomarker for low grade serous ovarian adenocarcinoma
L. L. Brunette1, D. DaSilva2, P. Mhawech-Fauceglia1 and W. M. Kast2
1LAC+USC Medical Center, Los Angeles, CA, 2Keck School of Medicine of USC, Los Angeles, CA
 
See more of: Poster Session
<< Previous Course | Next Course >>